Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Buttari

Showing results (21-30 of 131) with videos related to

Pageof 14
Sort By:
Frontiers in Neuroscience|January 10, 2018
<i>De novo</i> Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's DiseaseAlba Di Pardo, Abdul Basit, Andrea Armirotti, et al.
Frontiers in Cellular Neuroscience|July 14, 2020
IL-6 in the Cerebrospinal Fluid Signals Disease Activity in Multiple SclerosisMario Stampanoni Bassi, Ennio Iezzi, Jelena Drulovic, et al.
Therapeutic Advances in Neurological Disorders|June 23, 2025
Cladribine tablets in the new multiple sclerosis eraFabio Buttari, Ettore Dolcetti, Francesca Romana Rizzo, et al.
Journal of Neuroimmunology|November 28, 2017
Nerve growth factor is elevated in the CSF of patients with multiple sclerosis and central neuropathic painFabrizia Monteleone, Carolina G Nicoletti, Mario Stampanoni Bassi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 27, 2013
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegenerationSilvia Rossi, Caterina Motta, Valeria Studer, et al.
Frontiers in Neurology|May 10, 2021
Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing-Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study)Diego Centonze, Roberta Fantozzi, Fabio Buttari, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2015
Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroadsLuca Prosperini, Pietro Annovazzi, Marco Capobianco, et al.
Neurology and Therapy|April 22, 2025
Effect of Anodal Transcranial Direct Current Stimulation on the Intensity of Post-dural Puncture Headache: Results of Two Randomized Sham Controlled TrialsBledar Gjikolaj, Mario Stampanoni Bassi, Antonio Bruno, et al.
Functional Neurology|February 14, 2013
Early treatment with high-dose interferon beta-1a reverses cognitive and cortical plasticity deficits in multiple sclerosisFrancesco Mori, Hajime Kusayanagi, Fabio Buttari, et al.
Frontiers in Neurology|February 4, 2020
A Novel Homozygous Variant in the Fork-Head-Associated Domain of Polynucleotide Kinase Phosphatase in a Patient Affected by Late-Onset Ataxia With Oculomotor Apraxia Type 4Rosa Campopiano, Rosangela Ferese, Fabio Buttari, et al.
Pageof 14

Showing results (21-30 of 131) with videos related to

Sort By:
Pageof 14
Frontiers in Neuroscience|January 10, 2018
<i>De novo</i> Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's DiseaseAlba Di Pardo, Abdul Basit, Andrea Armirotti, et al.
Frontiers in Cellular Neuroscience|July 14, 2020
IL-6 in the Cerebrospinal Fluid Signals Disease Activity in Multiple SclerosisMario Stampanoni Bassi, Ennio Iezzi, Jelena Drulovic, et al.
Therapeutic Advances in Neurological Disorders|June 23, 2025
Cladribine tablets in the new multiple sclerosis eraFabio Buttari, Ettore Dolcetti, Francesca Romana Rizzo, et al.
Journal of Neuroimmunology|November 28, 2017
Nerve growth factor is elevated in the CSF of patients with multiple sclerosis and central neuropathic painFabrizia Monteleone, Carolina G Nicoletti, Mario Stampanoni Bassi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 27, 2013
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegenerationSilvia Rossi, Caterina Motta, Valeria Studer, et al.
Frontiers in Neurology|May 10, 2021
Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing-Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study)Diego Centonze, Roberta Fantozzi, Fabio Buttari, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2015
Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroadsLuca Prosperini, Pietro Annovazzi, Marco Capobianco, et al.
Neurology and Therapy|April 22, 2025
Effect of Anodal Transcranial Direct Current Stimulation on the Intensity of Post-dural Puncture Headache: Results of Two Randomized Sham Controlled TrialsBledar Gjikolaj, Mario Stampanoni Bassi, Antonio Bruno, et al.
Functional Neurology|February 14, 2013
Early treatment with high-dose interferon beta-1a reverses cognitive and cortical plasticity deficits in multiple sclerosisFrancesco Mori, Hajime Kusayanagi, Fabio Buttari, et al.
Frontiers in Neurology|February 4, 2020
A Novel Homozygous Variant in the Fork-Head-Associated Domain of Polynucleotide Kinase Phosphatase in a Patient Affected by Late-Onset Ataxia With Oculomotor Apraxia Type 4Rosa Campopiano, Rosangela Ferese, Fabio Buttari, et al.
Pageof 14